All In MedTech

FDA Clearance Tracker · P100014-S031

Solesta (Injectable Gel)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 27, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 27, 2021

Approved

Time to decision

177 days

Received May 3, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P100014-S031
Device name
Solesta (Injectable Gel)
Applicant location
Santa Barbara, CA
Received
May 3, 2021
Decided
Oct 27, 2021
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P100014

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

Approval to implement electronic labeling and changes to the labeling including revised contraindication, new warnings and new precautions.

Source documents

Other decisions for Palette Life Sciences

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.